Ones To Watch News
Refine Search
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
Swedish biotech Biosergen saw its shares close down 14.4% at 1.37 kronor yesterday after it revealed a co-development and licensing deal with Indian drugmaker Alkem Laboratories for BSG005, an innovative polyene macrolide, through Phase II and phase III trials for sale in the Indian market. 27 September 2023
Pharmaceutical
USA-based Ionis Pharmaceuticals yesterday released positive top-line results for the Phase III Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a rare genetic disorder. 27 September 2023
Biotechnology
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Coherus BioSciences’ application for Udenyca Onbody, the company's on-body injector (OBI) form of Udenyca (pegfilgrastim-cbqv). 26 September 2023
Biotechnology
California, USA-based biotech AcuraStem has entered into a license agreement with Japan’s largest pharma company Takeda to develop and commercialize AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of amyotrophic lateral sclerosis (ALS). 26 September 2023
Pharmaceutical
A $250 million private financing for California’s BridgeBio Pharma will support a possible launch of acoramidis, as well as further late-stage pipeline development. 26 September 2023
Pharmaceutical
Australian dermatology company Botanix today revealed it has received a communication from the US Food and Drug Administration (FDA) in relation to its New Drug Application (NDA) submission for sofpironium bromide (SB) gel, 15%. 26 September 2023
Biotechnology
Ahead of an advisory panel meeting of the US Food and Drug Administration’s scientists, the agency’s briefing notes paint a pessimistic picture for the amyotrophic lateral sclerosis (ALS) candidate NurOwn (autologous MSC-NTF cells). 26 September 2023
Pharmaceutical
Danish company Acesion Pharma has closed an oversubscribed Series B financing round, raising around 43 million euros ($48 million) to support its work in atrial fibrillation (AF). 26 September 2023
Biotechnology
Two Chinese contract development and manufacturing organizations (CDMO) with significant US operations have agreed to collaborate in the growth area of mRNA manufacturing. 25 September 2023
Pharmaceutical
Continuing its recent strong investment in the area of oncology, French privately-held company Pierre Fabre has inked a new drug discovery deal with British firm Vernalis. 25 September 2023
Pharmaceutical
French biopharma company Inventiva saw its US traded shares jump 11.1% to $4.19 yesterday, after it announced a deal with Japan-based Hepalys Pharma, a company incubated by Catalys Pacific. 22 September 2023
Biotechnology
Australian allogenic cellular medicines developer Mesoblast closed down 3.4% at A$1.265 yesterday, after it provided an update on the path to approval for its lead-product candidate Ryoncil. 22 September 2023
Pharmaceutical
Shares of Travere Therapeutics plunged more than 40% to $7.65 yesterday after it released top-line two-year confirmatory secondary endpoint results from the pivotal head-to-head Phase III PROTECT study of Filspari (sparsentan) in IgA nephropathy (IgAN), which narrowly missed eGFR total slope endpoint compare to irbesartan. 22 September 2023
Pharmaceutical
Accent Therapeutics, a US biopharma company developing a new class of small molecule precision cancer therapies, has announced three appointments in one at what is a pivotal time for the firm. 21 September 2023
Biotechnology
A new collaboration will see Californian biotech Kezar Life Sciences and China’s Everest Medicines working together on an immunoproteasome blocker, zetomipzomib. 21 September 2023
Biotechnology
French CNS and eye disease genetic medicines firm Coave Therapeutics has appointed Lolita Petit, as chief scientific officer (CSO). 21 September 2023
Pharmaceutical
Dutch firm Anavo Therapeutics, which claims to be the first company to systematically drug phosphatases, has named Shaun McNulty its chief scientific officer (CSO). 21 September 2023
Pharmaceutical
Florida-based central nervous system (CNS) specialist Relmada Therapeutics has announced positive results from a late-stage trial of REL-1017. 21 September 2023
Pharmaceutical
The US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for Neffy (epinephrine nasal spray) in the treatment of allergic reactions (Type I), including anaphylaxis for adults and children ≥30 kg. 21 September 2023
Biotechnology
Precision medicine specialist Rezo Therapeutics has appointed Nadir Mahmood as chief executive officer, replacing co-founder Nevan Krogan, who has held the role on an interim basis. 20 September 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze